Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-017526
Filing Date
2017-08-14
Accepted
2017-08-14 07:07:26
Documents
71
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atnx-10q_20170630.htm 10-Q 3175358
2 EX-31.1 atnx-ex311_256.htm EX-31.1 13684
3 EX-31.2 atnx-ex312_257.htm EX-31.2 13492
4 EX-32.1 atnx-ex321_258.htm EX-32.1 6779
  Complete submission text file 0001564590-17-017526.txt   10408064

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT atnx-20170630.xml EX-101.INS 2457146
6 XBRL TAXONOMY EXTENSION SCHEMA atnx-20170630.xsd EX-101.SCH 57417
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atnx-20170630_cal.xml EX-101.CAL 52042
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atnx-20170630_def.xml EX-101.DEF 232397
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atnx-20170630_lab.xml EX-101.LAB 481604
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atnx-20170630_pre.xml EX-101.PRE 381094
Mailing Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203
Business Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203 716-898-8625
Athenex, Inc. (Filer) CIK: 0001300699 (see all company filings)

EIN.: 431985966 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38112 | Film No.: 171026843
SIC: 2834 Pharmaceutical Preparations